Bal Pharma

Bal Pharma Net Debt / EBITDA

The Net Debt to EBITDA of Bal Pharma (BALPHARMA.NS) as of Nov 2, 2026 is 6.60. In the previous year, Net Debt to EBITDA was 4.40 — a change of 49.92% (higher).

Net Debt / EBITDA

6.60

YoY

49.92%

Last updated:

Net Debt to EBITDA of Bal Pharma is 2026 6.60 . Net Debt to EBITDA of Bal Pharma was 2025 4.40 . It decreases by 49.92% higher compared to the previous year.

The Bal Pharma Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2019
6.68 INR
Jan 1, 2020
23.07 INR
Jan 1, 2021
4.26 INR
Jan 1, 2022
2.93 INR
Jan 1, 2023
4.82 INR
Jan 1, 2024
3.56 INR
Jan 1, 2025
4.40 INR
Jan 1, 2026
6.60 INR
The Bal Pharma Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
6.60+49.92%
4.40+23.78%
3.56-26.17%
4.82+64.68%
2.93-31.36%
4.26-81.52%
23.07+245.34%
6.68+19.36%
5.60-9.98%
6.22+16.28%
5.35+125.40%
2.37-11.08%
2.67-9.91%
2.96-33.57%
4.46-42.16%
7.71-62.07%
20.32+285.79%
5.27-9.88%
5.84-0.49%
5.87—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bal Pharma Stock analysis

What does Bal Pharma do? Bal Pharma Ltd. generates revenue through the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company specializes in bulk actives, prescription drugs, generics, and pharma intermediates, targeting therapeutic areas such as anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. Its product portfolio includes APIs like antihistamine, platelet inhibitor, anti-diabetic, and anti-inflammatory agents, alongside finished formulations in tablets, capsules, syrups, and ointments. Key brands such as ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP are marketed to healthcare providers and consumers in these therapeutic segments. The company sells its APIs to other pharmaceutical manufacturers for further processing into finished products, while its finished formulations are distributed to hospitals, pharmacies, and clinics. Brands like AYURFINE and MENOLEAP CAPSULES target specific patient groups, such as those requiring anti-inflammatory or menopause treatment, respectively. The natural medicine line, including AYURSULIN and PROLIFE, caters to consumers seeking alternative treatments in diabetes and reproductive health. Revenue is derived from both B2B sales of APIs and direct B2C or B2B2C sales of branded formulations across multiple therapeutic categories. Bal Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bal Pharma stock

Net Debt to EBITDA of Bal Pharma is 6.60 in 2026.

Net Debt to EBITDA of Bal Pharma changed from 4.40 to 6.60, representing a 49.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Bal Pharma since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Bal Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Bal Pharma

All Key Metrics — Bal Pharma